Home » Stocks » TERN

Terns Pharmaceuticals, Inc. (TERN)

Stock Price: $17.13 USD -1.41 (-7.61%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 429.91M
Revenue (ttm) n/a
Net Income (ttm) -39.90M
Shares Out 23.89M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $17.13
Previous Close $18.54
Change ($) -1.41
Change (%) -7.61%
Day's Open 19.89
Day's Range 15.73 - 21.00
Day's Volume 167,072
52-Week Range 14.83 - 27.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio ...

GlobeNewsWire - 3 weeks ago

FOSTER CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio ...

GlobeNewswire - 1 month ago

FOSTER CITY, Calif. -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

Business Wire - 1 month ago

FOSTER CITY, Calif.--Terns Pharmaceuticals, Inc. (“Terns” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination th...

SEC - 1 month ago

Terns Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

NASDAQ - 1 month ago

Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Business Wire - 1 month ago

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy...

About TERN

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for which there is currently no approved therapy in the United States or Europe. NASH is a multifaceted disease that involves thre... [Read more...]

Industry
Medicinal and Botanical Manufacturing
IPO Date
Feb 5, 2021
CEO
Senthil Sundaram
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
TERN
Full Company Profile

Financial Performance

Financial Statements